PT-141 (Bremelanotide) for Women: The Complete Q&A
Bremelanotide, research name PT-141, is the melanocortin-receptor agonist behind Vyleesi®, the FDA-approved as-needed injection for acquired, generalized hypoactive sexual desire disorder in premenopausal women. It acts on receptors in the central nervous system rather than on blood vessels, which makes it unlike every Viagra®-class drug. Nausea is its famous companion. Here is the whole picture.
Reviewed by board-certified physicians · Published 2026-08-28 · Updated 2026-08-28 · 9 min read
Key facts
Bremelanotide is FDA-approved as Vyleesi®, an as-needed subcutaneous injection for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women.
It is a melanocortin-receptor agonist acting in the central nervous system, a different mechanism from vasoactive drugs like sildenafil.
It is used as needed before anticipated intimacy, with labeled limits: no more than one dose in 24 hours and no more than eight doses per month.
Nausea was the most common side effect in trials, affecting roughly 40% of participants, most prominently around early doses.
It transiently raises blood pressure after dosing, and is not for women with uncontrolled hypertension or cardiovascular disease.
Compounded PT-141 products, including nasal sprays, are not FDA-approved; the approved format is the injection.
How is PT-141 different from Viagra®-class medication?
Every PDE5 drug is a vascular tool: it amplifies local blood-vessel response and was developed around male physiology. Bremelanotide is categorically different. It is a peptide that activates melanocortin receptors in the central nervous system, pathways involved in sexual response upstream of any vascular event. It was developed specifically for a desire disorder in women, on the reasoning that desire is regulated in signaling, not plumbing.
That mechanistic difference explains the practical differences users notice: it is not taken to produce a physical response on cue, its labeled outcome measures were about desire and associated distress, and its side effects, nausea foremost, are the side effects of central peptide signaling rather than of vasodilation.
What is HSDD, and why does the diagnosis matter so much?
Hypoactive sexual desire disorder is the persistent, distressing absence of sexual desire not better explained by a medical condition, a medication, a relationship circumstance, or another psychiatric condition. Every word is load-bearing: distressing, because low desire without distress is not a disorder; acquired and generalized, in the labeled indication, meaning desire was previously present and its absence is not situational to one context; and the exclusions, because low desire is frequently the visible symptom of something else, thyroid disease, depression, an SSRI, exhaustion, relationship strain.
The diagnosis is the treatment decision. A physician working through it properly is distinguishing the situations bremelanotide was studied for from the many look-alikes it was not, which is precisely what a prescription-mill checkout flow cannot do. The wider landscape of options, and how physicians sort among them, is mapped in our prescription options overview.
What did the trials actually show?
In the phase 3 program that produced approval, premenopausal women with acquired, generalized HSDD using bremelanotide as needed reported statistically significant improvements versus placebo in validated desire scores and in distress associated with low desire. Framed plainly: meaningful average improvements on the instruments the condition is measured with, in the studied population, not a promise of any particular outcome, and individual results vary and are not typical.
The trial program is also the source of the drug's practical rulebook, the dose limits, the nausea data, the blood-pressure observations, which is why the rules deserve respect rather than improvisation.
3/mo CHROMA23+ Membership, medication priced separately, every cost shown first.
Roughly four in ten trial participants experienced nausea, concentrated around the first doses, mostly rated mild to moderate, and a minority found it reason to stop. Clinicians manage it with the unglamorous toolkit: dosing well ahead of activity, avoiding a full stomach at dosing time, anti-nausea strategies where appropriate, and, importantly, the observation that for many women it attenuates with subsequent doses as the body acclimates.
The realistic framing for a first-time user: plan for the possibility during your first few doses, decide in advance it is data rather than verdict, and report persistent or severe nausea to the prescriber, because tolerability is exactly the kind of thing the follow-up exists for.
What are the other rules and cautions worth knowing?
The labeled usage limits are firm: one dose per 24 hours, eight per month, taken as needed before anticipated intimacy. Bremelanotide transiently raises blood pressure and slows heart rate for a period after each dose, which is why uncontrolled hypertension and cardiovascular disease sit in the do-not-use column and why a real blood-pressure history belongs in the evaluation. Focal skin darkening, hyperpigmentation of the face, gums, or breasts, occurred in a small percentage of trial participants, more with frequent use, and darker skin tones carried higher likelihood; it did not always fully resolve after stopping.
Two more practicalities: it can slow gastric emptying enough to matter for the absorption timing of some oral medications, a pharmacist-level detail worth flagging with your full medication list, and it is not for use in pregnancy, with reliable contraception part of the labeled conversation for women who could become pregnant.
What about compounded PT-141?
Compounded PT-141 exists because bremelanotide is a component of an FDA-approved drug, which places it among the peptides pharmacies may lawfully compound under the usual patient-specific rules; that is a meaningfully different legal position from the internet's gray-market research peptides, and a distinction covered at length in our compounding legality explainer. Compounded formats, injections at pharmacy-set concentrations and nasal sprays most visibly, are not FDA-approved products, carry no trials of their own, and inherit their evidence secondhand from the approved injection's program.
The practical guidance is the standard one, applied to an unusually hype-prone corner of the internet: physician evaluation, verifiable state-licensed pharmacy, labeled product, and skepticism toward peptide storefronts selling vials without any of that. The nasal-versus-injection question specifically gets its own treatment in our comparison.
Frequently asked questions
How long before intimacy is it taken, and how long do effects last?
The label directs dosing at least 45 minutes before anticipated activity, and trial participants' windows extended for hours afterward; individual timing settles with experience. It is not an instant-response product, and treating it like one mostly buys nausea at an unhelpful moment.
Does PT-141 work for men?
Bremelanotide's development history includes male ED research, and its approval is for premenopausal women with HSDD. Male use is off-label physician territory with a thinner evidence base, mostly discussed where standard ED pathways have failed; see our men's options ladder for that landscape.
Is the skin-darkening effect common?
It occurred in a small minority in trials, with higher likelihood at frequent dosing and in darker skin tones, and did not always fully resolve. It is dose-frequency-related, which is one more reason the eight-per-month ceiling is a ceiling and not a suggestion.
Can I use PT-141 while on an antidepressant?
Sometimes, and the question is genuinely for the prescriber, because low desire itself can be an antidepressant effect, which changes the right move entirely. Adjusting the antidepressant, where safe, sometimes addresses the underlying issue better than adding a peptide on top.
Is Vyleesi® still available?
The product changed corporate hands in recent years and availability through ordinary channels has been inconsistent enough that patients ask. Where the branded injection is impractical to obtain, the compounded conversation is precisely the kind of clinical-need determination a physician documents; supply questions are answerable at evaluation time rather than in an article.
About CHROMA23®
CHROMA23® is a clinical weight loss platform built on prescription protocols: injectables, oral medicine, and the protocols that come next, under one 3 membership. Every prescription decision is made by an independent, board-certified physician licensed in the patient's state, and every medication is dispensed by a state-licensed pharmacy. The assessment is free. The membership is 3. The medicine is real. The physician is real.
This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Compounded medications are not FDA-approved. Always consult a board-certified physician about your individual situation. Figures from named clinical trials describe study populations; individual results vary and are not typical.